Safety Profile of Paxlovid in the Treatment of COVID-19

• Published in: Current pharmaceutical design Vol. 30; no. 9; p. 666
• Main Authors: Lv, Bing, Gao, Xin, Zeng, Guoqiang, Guo, Hui, Li, Faping
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2024
• Subjects: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; COVID-19 - epidemiology; COVID-19 Drug Treatment; Female; Humans; Male; Middle Aged; SARS-CoV-2 - drug effects; United States - epidemiology; United States Food and Drug Administration; United States; COVID-19; Paxlovid; FAERS; adverse events; diarrhea; antiviral drug

With the urgent and widespread application of Paxlovid, a novel antiviral drug for Coronavirus Disease 2019 (COVID-19) in clinical practice, concerns regarding its actual efficacy and safety have emerged. In order to provide more evidence to support its clinical application, we sought to perform a d...